What they say: Introduction:
A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July 2014 issue of the journal “EMBO”, by Prof Sinclair, North BJ, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Glycolipid-based Lifespan extension therapy: α-galactosylceramide (α-GalCer), a synthetic glycolipid, increases life span via up-regulation of its target gene BubR1
What is known?
α-galactosylceramide (α-GalCer) has been shown to protect against autoimmune diseases, including TIDM. However, the exact mechanism of action is far from clear.
From Research Findings to Therapeutic Opportunity:
This study suggests, for the first time, that α-galactosylceramide (α-GalCer), by increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).
Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “α-galactosylceramide (α-GalCer) or its analogues, either alone or in combination with other drugs,” may be used to extend the lifespan of an individual (fig. 1).
Details on the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Undisclosed mechanistic information: How α-galactosylceramide (α-GalCer) increases the expression of BubR1 and extends mammalian life-span
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
# Research cooperation
Citation: Boominathan, L., Glycolipid-based Lifespan extension therapy: α-galactosylceramide (α-GalCer), a synthetic glycolipid, increases life span via up-regulation of its target gene BubR1, 18/May/2018, 1.29 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com